Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma

BACKGROUND: The insulin‐like growth factor‐1 (IGF‐1) signaling pathway plays an important role in the pathology of Ewing sarcoma (ES). Retrospective studies have suggested that levels of IGF‐1 and IGF binding protein 3 (IGFBP‐3) are correlated with the outcome of patients with ES. METHODS: The IGF‐1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2011-11, Vol.117 (21), p.4966-4976
Hauptverfasser: Borinstein, Scott C., Barkauskas, Donald A., Krailo, Mark, Scher, Daniel, Scher, Lauren, Schlottmann, Silke, Kallakury, Bhaskar, Dickman, Paul S., Pawel, Bruce R., West, Daniel C., Womer, Richard B., Toretsky, Jeffrey A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4976
container_issue 21
container_start_page 4966
container_title Cancer
container_volume 117
creator Borinstein, Scott C.
Barkauskas, Donald A.
Krailo, Mark
Scher, Daniel
Scher, Lauren
Schlottmann, Silke
Kallakury, Bhaskar
Dickman, Paul S.
Pawel, Bruce R.
West, Daniel C.
Womer, Richard B.
Toretsky, Jeffrey A.
description BACKGROUND: The insulin‐like growth factor‐1 (IGF‐1) signaling pathway plays an important role in the pathology of Ewing sarcoma (ES). Retrospective studies have suggested that levels of IGF‐1 and IGF binding protein 3 (IGFBP‐3) are correlated with the outcome of patients with ES. METHODS: The IGF‐1 signaling pathway was investigated prospectively in 269 patients who had localized, previously untreated ES. Serum samples were obtained at diagnosis, and concentrations of IGF‐1 and IGFBP‐3 were determined by enzyme‐linked immunosorbent assays. In addition, immunohistochemistry (IHC) was performed to assay for phosphorylated p70S6 kinase, protein kinase B (Akt), and forkhead box protein O1 (FOXO1) and to determine the presence of protein tyrosine phosphatase‐L1 (PTPL1). IHC findings along with IGF‐1 and IGFBP‐3 concentrations were correlated with age, tumor location, sex, event‐free survival, and overall survival. RESULTS: Patients aged >18 years tended to have higher levels of IGF‐1 (P = .10), lower levels of IGFBP‐3 (P = .16), and decreased IGFBP‐3:IGF‐1 ratios (P = .01). No correlations were observed between sex, tumor location, or outcomes and concentrations of IGF‐1 or IGFBP‐3. Phosphorylation of p70S6 kinase, Akt, and FOXO1 was detected in the majority of patient tissues but was not associated with age, sex, or tumor location. PTPL1 was present in >80% of tumors and also was not correlated with age, sex, or tumor location. There was no difference in survival with respect to the presence of phosphorylated p70S6 kinase, phosphorylated FOXO1, phosphorylated Akt, or PTPL1. CONCLUSIONS: The baseline IGFBP‐3:IGF‐1 ratio was correlated with age but did not affect the outcomes of patients with ES. The authors concluded that additional investigation of the IGF‐1 pathway is warranted in patients with ES, and especially in those who have received treatment with IGF‐1 receptor antibody inhibitors. Cancer 2011;. © 2011 American Cancer Society. The authors investigated the insulin‐like growth factor‐1 (IGF‐1) signaling pathway in patients with newly diagnosed Ewing sarcoma. The baseline IGF‐1:IGF binding protein‐3 (IGFBP‐3) ratio was correlated with age but not with patient outcomes. IGF‐1 levels, IGFBP‐3 levels, and phosphorylation of downstream signaling targets of IGF‐1 pathway activation were not correlated with survival.
doi_str_mv 10.1002/cncr.26112
format Article
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_cncr_26112_CNCR26112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR26112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1192-ac0ad996983938fe20a2d90585cb351c6f635a7cda05789f60a94cebf20f7c083</originalsourceid><addsrcrecordid>eNotkMFOhDAQhhujibh68Qn6AqzTlgI9GrLqJhtNjCbeyFBaqLKwoShZTz6Cz-iTCKun-ef_Z_7DR8glgyUD4Fe61f2Sx4zxIxIwUEkILOLHJACANJSReDklZ96_TmvCpQhIsW4_jB9chYPrWtpZOtSGuta_N679-fpu3JuhVd-NQ00t6qHrJ5NR76oWp4uK7nCoR9xPL7Tp9OR9mpKuxjny2Otui-fkxGLjzcX_XJDnm9VTdhduHm7X2fUm1IwpHqIGLJWKVSqUSK3hgLxUIFOpCyGZjm0sJCa6RJBJqmwMqCJtCsvBJhpSsSDsr3d0jdnnu95tsd_nDPIZTT6jyQ9o8uw-ezwo8Qufel0C</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma</title><source>Wiley Free Archive</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Borinstein, Scott C. ; Barkauskas, Donald A. ; Krailo, Mark ; Scher, Daniel ; Scher, Lauren ; Schlottmann, Silke ; Kallakury, Bhaskar ; Dickman, Paul S. ; Pawel, Bruce R. ; West, Daniel C. ; Womer, Richard B. ; Toretsky, Jeffrey A.</creator><creatorcontrib>Borinstein, Scott C. ; Barkauskas, Donald A. ; Krailo, Mark ; Scher, Daniel ; Scher, Lauren ; Schlottmann, Silke ; Kallakury, Bhaskar ; Dickman, Paul S. ; Pawel, Bruce R. ; West, Daniel C. ; Womer, Richard B. ; Toretsky, Jeffrey A.</creatorcontrib><description>BACKGROUND: The insulin‐like growth factor‐1 (IGF‐1) signaling pathway plays an important role in the pathology of Ewing sarcoma (ES). Retrospective studies have suggested that levels of IGF‐1 and IGF binding protein 3 (IGFBP‐3) are correlated with the outcome of patients with ES. METHODS: The IGF‐1 signaling pathway was investigated prospectively in 269 patients who had localized, previously untreated ES. Serum samples were obtained at diagnosis, and concentrations of IGF‐1 and IGFBP‐3 were determined by enzyme‐linked immunosorbent assays. In addition, immunohistochemistry (IHC) was performed to assay for phosphorylated p70S6 kinase, protein kinase B (Akt), and forkhead box protein O1 (FOXO1) and to determine the presence of protein tyrosine phosphatase‐L1 (PTPL1). IHC findings along with IGF‐1 and IGFBP‐3 concentrations were correlated with age, tumor location, sex, event‐free survival, and overall survival. RESULTS: Patients aged &gt;18 years tended to have higher levels of IGF‐1 (P = .10), lower levels of IGFBP‐3 (P = .16), and decreased IGFBP‐3:IGF‐1 ratios (P = .01). No correlations were observed between sex, tumor location, or outcomes and concentrations of IGF‐1 or IGFBP‐3. Phosphorylation of p70S6 kinase, Akt, and FOXO1 was detected in the majority of patient tissues but was not associated with age, sex, or tumor location. PTPL1 was present in &gt;80% of tumors and also was not correlated with age, sex, or tumor location. There was no difference in survival with respect to the presence of phosphorylated p70S6 kinase, phosphorylated FOXO1, phosphorylated Akt, or PTPL1. CONCLUSIONS: The baseline IGFBP‐3:IGF‐1 ratio was correlated with age but did not affect the outcomes of patients with ES. The authors concluded that additional investigation of the IGF‐1 pathway is warranted in patients with ES, and especially in those who have received treatment with IGF‐1 receptor antibody inhibitors. Cancer 2011;. © 2011 American Cancer Society. The authors investigated the insulin‐like growth factor‐1 (IGF‐1) signaling pathway in patients with newly diagnosed Ewing sarcoma. The baseline IGF‐1:IGF binding protein‐3 (IGFBP‐3) ratio was correlated with age but not with patient outcomes. IGF‐1 levels, IGFBP‐3 levels, and phosphorylation of downstream signaling targets of IGF‐1 pathway activation were not correlated with survival.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.26112</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Akt ; Ewing sarcoma ; forkhead box protein O1 ; insulin‐like growth factor 1 ; insulin‐like growth factor binding protein‐3 ; p70S6 kinase ; protein tyrosine phosphatase‐L1</subject><ispartof>Cancer, 2011-11, Vol.117 (21), p.4966-4976</ispartof><rights>Copyright © 2011 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1192-ac0ad996983938fe20a2d90585cb351c6f635a7cda05789f60a94cebf20f7c083</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.26112$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.26112$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids></links><search><creatorcontrib>Borinstein, Scott C.</creatorcontrib><creatorcontrib>Barkauskas, Donald A.</creatorcontrib><creatorcontrib>Krailo, Mark</creatorcontrib><creatorcontrib>Scher, Daniel</creatorcontrib><creatorcontrib>Scher, Lauren</creatorcontrib><creatorcontrib>Schlottmann, Silke</creatorcontrib><creatorcontrib>Kallakury, Bhaskar</creatorcontrib><creatorcontrib>Dickman, Paul S.</creatorcontrib><creatorcontrib>Pawel, Bruce R.</creatorcontrib><creatorcontrib>West, Daniel C.</creatorcontrib><creatorcontrib>Womer, Richard B.</creatorcontrib><creatorcontrib>Toretsky, Jeffrey A.</creatorcontrib><title>Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma</title><title>Cancer</title><description>BACKGROUND: The insulin‐like growth factor‐1 (IGF‐1) signaling pathway plays an important role in the pathology of Ewing sarcoma (ES). Retrospective studies have suggested that levels of IGF‐1 and IGF binding protein 3 (IGFBP‐3) are correlated with the outcome of patients with ES. METHODS: The IGF‐1 signaling pathway was investigated prospectively in 269 patients who had localized, previously untreated ES. Serum samples were obtained at diagnosis, and concentrations of IGF‐1 and IGFBP‐3 were determined by enzyme‐linked immunosorbent assays. In addition, immunohistochemistry (IHC) was performed to assay for phosphorylated p70S6 kinase, protein kinase B (Akt), and forkhead box protein O1 (FOXO1) and to determine the presence of protein tyrosine phosphatase‐L1 (PTPL1). IHC findings along with IGF‐1 and IGFBP‐3 concentrations were correlated with age, tumor location, sex, event‐free survival, and overall survival. RESULTS: Patients aged &gt;18 years tended to have higher levels of IGF‐1 (P = .10), lower levels of IGFBP‐3 (P = .16), and decreased IGFBP‐3:IGF‐1 ratios (P = .01). No correlations were observed between sex, tumor location, or outcomes and concentrations of IGF‐1 or IGFBP‐3. Phosphorylation of p70S6 kinase, Akt, and FOXO1 was detected in the majority of patient tissues but was not associated with age, sex, or tumor location. PTPL1 was present in &gt;80% of tumors and also was not correlated with age, sex, or tumor location. There was no difference in survival with respect to the presence of phosphorylated p70S6 kinase, phosphorylated FOXO1, phosphorylated Akt, or PTPL1. CONCLUSIONS: The baseline IGFBP‐3:IGF‐1 ratio was correlated with age but did not affect the outcomes of patients with ES. The authors concluded that additional investigation of the IGF‐1 pathway is warranted in patients with ES, and especially in those who have received treatment with IGF‐1 receptor antibody inhibitors. Cancer 2011;. © 2011 American Cancer Society. The authors investigated the insulin‐like growth factor‐1 (IGF‐1) signaling pathway in patients with newly diagnosed Ewing sarcoma. The baseline IGF‐1:IGF binding protein‐3 (IGFBP‐3) ratio was correlated with age but not with patient outcomes. IGF‐1 levels, IGFBP‐3 levels, and phosphorylation of downstream signaling targets of IGF‐1 pathway activation were not correlated with survival.</description><subject>Akt</subject><subject>Ewing sarcoma</subject><subject>forkhead box protein O1</subject><subject>insulin‐like growth factor 1</subject><subject>insulin‐like growth factor binding protein‐3</subject><subject>p70S6 kinase</subject><subject>protein tyrosine phosphatase‐L1</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotkMFOhDAQhhujibh68Qn6AqzTlgI9GrLqJhtNjCbeyFBaqLKwoShZTz6Cz-iTCKun-ef_Z_7DR8glgyUD4Fe61f2Sx4zxIxIwUEkILOLHJACANJSReDklZ96_TmvCpQhIsW4_jB9chYPrWtpZOtSGuta_N679-fpu3JuhVd-NQ00t6qHrJ5NR76oWp4uK7nCoR9xPL7Tp9OR9mpKuxjny2Otui-fkxGLjzcX_XJDnm9VTdhduHm7X2fUm1IwpHqIGLJWKVSqUSK3hgLxUIFOpCyGZjm0sJCa6RJBJqmwMqCJtCsvBJhpSsSDsr3d0jdnnu95tsd_nDPIZTT6jyQ9o8uw-ezwo8Qufel0C</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Borinstein, Scott C.</creator><creator>Barkauskas, Donald A.</creator><creator>Krailo, Mark</creator><creator>Scher, Daniel</creator><creator>Scher, Lauren</creator><creator>Schlottmann, Silke</creator><creator>Kallakury, Bhaskar</creator><creator>Dickman, Paul S.</creator><creator>Pawel, Bruce R.</creator><creator>West, Daniel C.</creator><creator>Womer, Richard B.</creator><creator>Toretsky, Jeffrey A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope/></search><sort><creationdate>20111101</creationdate><title>Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma</title><author>Borinstein, Scott C. ; Barkauskas, Donald A. ; Krailo, Mark ; Scher, Daniel ; Scher, Lauren ; Schlottmann, Silke ; Kallakury, Bhaskar ; Dickman, Paul S. ; Pawel, Bruce R. ; West, Daniel C. ; Womer, Richard B. ; Toretsky, Jeffrey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1192-ac0ad996983938fe20a2d90585cb351c6f635a7cda05789f60a94cebf20f7c083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Akt</topic><topic>Ewing sarcoma</topic><topic>forkhead box protein O1</topic><topic>insulin‐like growth factor 1</topic><topic>insulin‐like growth factor binding protein‐3</topic><topic>p70S6 kinase</topic><topic>protein tyrosine phosphatase‐L1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borinstein, Scott C.</creatorcontrib><creatorcontrib>Barkauskas, Donald A.</creatorcontrib><creatorcontrib>Krailo, Mark</creatorcontrib><creatorcontrib>Scher, Daniel</creatorcontrib><creatorcontrib>Scher, Lauren</creatorcontrib><creatorcontrib>Schlottmann, Silke</creatorcontrib><creatorcontrib>Kallakury, Bhaskar</creatorcontrib><creatorcontrib>Dickman, Paul S.</creatorcontrib><creatorcontrib>Pawel, Bruce R.</creatorcontrib><creatorcontrib>West, Daniel C.</creatorcontrib><creatorcontrib>Womer, Richard B.</creatorcontrib><creatorcontrib>Toretsky, Jeffrey A.</creatorcontrib><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borinstein, Scott C.</au><au>Barkauskas, Donald A.</au><au>Krailo, Mark</au><au>Scher, Daniel</au><au>Scher, Lauren</au><au>Schlottmann, Silke</au><au>Kallakury, Bhaskar</au><au>Dickman, Paul S.</au><au>Pawel, Bruce R.</au><au>West, Daniel C.</au><au>Womer, Richard B.</au><au>Toretsky, Jeffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma</atitle><jtitle>Cancer</jtitle><date>2011-11-01</date><risdate>2011</risdate><volume>117</volume><issue>21</issue><spage>4966</spage><epage>4976</epage><pages>4966-4976</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>BACKGROUND: The insulin‐like growth factor‐1 (IGF‐1) signaling pathway plays an important role in the pathology of Ewing sarcoma (ES). Retrospective studies have suggested that levels of IGF‐1 and IGF binding protein 3 (IGFBP‐3) are correlated with the outcome of patients with ES. METHODS: The IGF‐1 signaling pathway was investigated prospectively in 269 patients who had localized, previously untreated ES. Serum samples were obtained at diagnosis, and concentrations of IGF‐1 and IGFBP‐3 were determined by enzyme‐linked immunosorbent assays. In addition, immunohistochemistry (IHC) was performed to assay for phosphorylated p70S6 kinase, protein kinase B (Akt), and forkhead box protein O1 (FOXO1) and to determine the presence of protein tyrosine phosphatase‐L1 (PTPL1). IHC findings along with IGF‐1 and IGFBP‐3 concentrations were correlated with age, tumor location, sex, event‐free survival, and overall survival. RESULTS: Patients aged &gt;18 years tended to have higher levels of IGF‐1 (P = .10), lower levels of IGFBP‐3 (P = .16), and decreased IGFBP‐3:IGF‐1 ratios (P = .01). No correlations were observed between sex, tumor location, or outcomes and concentrations of IGF‐1 or IGFBP‐3. Phosphorylation of p70S6 kinase, Akt, and FOXO1 was detected in the majority of patient tissues but was not associated with age, sex, or tumor location. PTPL1 was present in &gt;80% of tumors and also was not correlated with age, sex, or tumor location. There was no difference in survival with respect to the presence of phosphorylated p70S6 kinase, phosphorylated FOXO1, phosphorylated Akt, or PTPL1. CONCLUSIONS: The baseline IGFBP‐3:IGF‐1 ratio was correlated with age but did not affect the outcomes of patients with ES. The authors concluded that additional investigation of the IGF‐1 pathway is warranted in patients with ES, and especially in those who have received treatment with IGF‐1 receptor antibody inhibitors. Cancer 2011;. © 2011 American Cancer Society. The authors investigated the insulin‐like growth factor‐1 (IGF‐1) signaling pathway in patients with newly diagnosed Ewing sarcoma. The baseline IGF‐1:IGF binding protein‐3 (IGFBP‐3) ratio was correlated with age but not with patient outcomes. IGF‐1 levels, IGFBP‐3 levels, and phosphorylation of downstream signaling targets of IGF‐1 pathway activation were not correlated with survival.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/cncr.26112</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2011-11, Vol.117 (21), p.4966-4976
issn 0008-543X
1097-0142
language eng
recordid cdi_wiley_primary_10_1002_cncr_26112_CNCR26112
source Wiley Free Archive; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Akt
Ewing sarcoma
forkhead box protein O1
insulin‐like growth factor 1
insulin‐like growth factor binding protein‐3
p70S6 kinase
protein tyrosine phosphatase‐L1
title Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T19%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20the%20insulin%E2%80%90like%20growth%20factor%E2%80%901%20signaling%20pathway%20in%20localized%20Ewing%20sarcoma&rft.jtitle=Cancer&rft.au=Borinstein,%20Scott%20C.&rft.date=2011-11-01&rft.volume=117&rft.issue=21&rft.spage=4966&rft.epage=4976&rft.pages=4966-4976&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.26112&rft_dat=%3Cwiley%3ECNCR26112%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true